Pediatrics

Partner With Us

Advertisement

FDA & Government News Conference News ENDO 2026

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Edited Kathryn Wighton

Conexiant May 29, 2026

Content Currently Unavailable

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.